Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10866MR)

This product GTTS-WQ10866MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Melanoma, Neuroblastoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10866MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4161MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ12963MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ4981MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ2214MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ5574MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP-771
GTTS-WQ15515MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-7858
GTTS-WQ470MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ6842MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DT-IL-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW